We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Accepts Novartis, Kite Pharma’s Personalized Cancer Treatments for Review
FDA Accepts Novartis, Kite Pharma’s Personalized Cancer Treatments for Review
The FDA has accepted for review the first two novel, personalized cancer treatments — known as chimeric antigen receptor T-cell therapies, or CAR-T — using immune system cells drawn from the blood and reprogrammed to target cancer cells.